Ultragenyx Pharmaceutical Inc. buy klostergang
Summary
This prediction ended on 01.11.18 with a price of €48.64. With a performance of -5.41%, the BUY prediction by klostergang finished with a loss. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Ultragenyx Pharmaceutical Inc. | -4.466% | -4.466% | 48.193% | -34.834% |
iShares Core DAX® | 1.164% | 1.549% | 24.351% | 23.659% |
iShares Nasdaq 100 | 0.118% | 0.969% | 28.865% | 41.786% |
iShares Nikkei 225® | 1.124% | -1.120% | 17.443% | 6.454% |
iShares S&P 500 | 0.479% | 1.068% | 28.585% | 42.511% |
Comments by klostergang for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
RARE and a PDUFA date in mid-April for burosumab in XLH is a major catalyst.
As for material catalysts to watch for, you look forward to the FDA decision on burosumab with a PDUFA date of April 17th. A decision by the EMA should be forthcoming in the first quarter. Also in the first half of the year we can expect a CHMP opinion for MEPSEVII. In the second half of the year we could potentially see a filing for regulatory approval for UX007 in patients with LC-FAOD should the FDA
accept their early filing. One also expect data from the second cohort of the phase 1/2 study for DTX301 in OTC deficiency around the same time frame.
Stopped prediction by klostergang for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
06.07.19
04.11.21
17.06.21